{"id":"W4413141479","doi":"10.1182/bloodadvances.2024015600","title":"Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC; Ottawa Hospital; University of Ottawa; Health Canada","funders":"Pharmacyclics; Genentech; Astellas Pharma; EUSA Pharma; Seagen; Regeneron Pharmaceuticals; Incyte; F. Hoffmann-La Roche; Kite Pharma; Gilead Sciences; Ipsen; BeiGene; Daiichi Sankyo Europe; University College London Hospitals NHS Foundation Trust; Sanofi; Swedish Orphan Biovitrum; Omeros Corporation; Spectrum Pharmaceuticals; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Refractory (planetary science); Clinical endpoint; Adverse effect; Lymphoma; Surgery; Gastroenterology; Oncology; Clinical trial; Hodgkin lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001323436,0.0002697705,0.0005488218,0.0001610459,0.0001657055,0.0000287992,0.0001164351,0.00006982349,0.00005279519],"category_scores_gemma":[0.0002804013,0.000182271,0.0001471506,0.0003335342,0.00006200251,0.0001448984,0.00004497497,0.00005107248,0.00001567818],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001690796,"about_ca_system_score_gemma":0.0003643846,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003756746,"about_ca_topic_score_gemma":0.0001026689,"domain_scores_codex":[0.9984999,0.00004224641,0.0003949609,0.0005091947,0.0002235091,0.0003301925],"domain_scores_gemma":[0.998768,0.0004075732,0.0001270537,0.0004642069,0.0001156911,0.0001174502],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.007848652,0.09076606,0.1774907,0.0006135147,0.002089717,0.001227331,0.0005203647,0.000003942855,0.001658791,0.0008495772,0.006833083,0.7100983],"study_design_scores_gemma":[0.2681644,0.02775059,0.1423629,0.0007691424,0.004790532,0.0001120738,0.002456088,0.0001224594,0.02590116,0.0005205396,0.5264,0.0006501384],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9841372,0.00847925,0.00008027724,0.0007662387,0.0004099875,0.002430623,0.00004993616,0.0001699223,0.003476502],"genre_scores_gemma":[0.9887374,0.0004808193,0.001748074,0.0004801381,0.0001649677,0.001157599,0.00004305114,0.00002710536,0.007160862],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7094482,"threshold_uncertainty_score":0.7432795,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02168455737675362,"score_gpt":0.352881388360296,"score_spread":0.3311968309835424,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}